Julian Upton

As part of its digital transformation, last year Novartis recruited Raj Patil, as Head of Data Strategy, and Shahram Ebadollahi as Head of Data Science and Advanced Analytics. Here they talk to Pharm Exec about the task that lies ahead.

Andre Heeg, Sandor's new Head of Digital, tells Pharm Exec about his digital vision for the company.

Hilary Hutton-Squire, Gilead’s UK & Ireland General Manager, talks to Pharm Exec about the company's new "HIV Age Positively" campaign.

Anjum Swaroop, Vice President and Head of IP at Dr. Reddy's, talks to Pharm Exec about her journey with the company and about what the future holds for this major US generics player.

As this year's ESMO gets under way, Pharm Exec spoke to James Campbell-global franchise business head at Merck KGaA, Darmstadt, Germany-to discuss his vision for the company as a global leader in oncology.

Pharm Exec speaks to Inovio Pharmaceutical's Dr. J. Joseph Kim about his journey from humble beginnings as an 11-year-old Korean immigrant to his present position at the forefront of a new medical frontier.

Over the last decade, Spain has seen a significant growth in venture-capital investment in the life sciences. We explore the driving forces.

At this month's AMPLEXOR Life Sciences’ “Be The Expert” conference, Pharm Exec caught up with Steve Gens, who talked about the evolution of Regulatory Information Management (RIM) and offered some predictions for 2022.

Ilyssa Levins talks to Pharm Exec about some of the regulatory, compliance and legal challenges posed by the digital health revolution.

Digital health is not at all about the app. It’s about the behavior of the individual patient, said Søren Smed Østergaard at this year's Digital Health World Congress in London.

CEO Helen Torley talks to Pharm Exec about her vision for Halozyme as a multi-product oncology biotech.

Pharm Exec talks to Rob Johnson, managing partner and co-founder of Alacrita, about pharma’s relationship with medical imaging.

To coincide with World Immunization Week, IFPMA's Thomas Cueni, chair of the AMR Industry Alliance, outlines the critical importance of vaccines in the fight against AMR and infectious diseases.

Practitioners in the field of HEOR training and education outline how the best courses are responding to advancing industry needs.

Looking at the balance of optimism and caution discussed at eyeforpharma Barcelona around pharma’s embrace of AI.

Pharm Exec speaks to James Burt, Accord Healthcare’s executive vice president, Europe and MENA, about the company’s vision for the UK and Europe post-Brexit, the challenges of retaining the company’s culture amid major growth, and the current landscape for generic medicines.

Pharm Exec speaks to Jane Griffiths, Global Head of Actelion, about the current state of the industry's reputation and the work that needs to be done to further build trust with patients and the public.

Sean McCarthy, President & CEO of CytomX, outlines the company’s journey from university startup to rising star of the immuno-oncology space.

Pharm Exec details the latest approaches to combating disease and health crises on a global scale-including industry perspectives from those involved on the front lines.

Killian Weiss talks to Pharm Exec about the modern challenges of identifying KOLs in oncology, and why technology can offer a solution to this vital process.

Pharm Exec speaks to Prognos CEO Sundeep Bhan about how the company’s unique offering will reach beyond life sciences as the long-promised benefits of AI become reality.

Selecta Biosciences CEO Dr. Werner Cautreels talks about the company's innovative technology and how his entrepreneurial experiences in big pharma prepared him for the challenge of a new startup.

Mary Lynne Hedley, president and COO of TESARO, talks to Pharm Exec about the company’s innovative approach to responsible drug development and commercialization, and how its theory of putting patients first is translated into practise.

Can the pharma industry truly achieve a patient-centric supply chain? How some clinical trial logistics companies are racing ahead in making the patient a key link in the chain.

Dr. Fumie Griego, the International Federation of Pharmaceutical Manufacturers and Associations’ new Assistant Director General, speaks with Pharm Exec about her mission to use IFPMA ’s international reach to find real and practical solutions to the most pressing global healthcare challenges.

Experts assess the current pharma dealmaking landscape-one where, despite market headwinds, is still heavily influenced by factors under the buyer and seller’s control.

With digital interventions in drug adherence regimes evolving to new levels of sophistication, Pharm Exec looks at the ongoing patient-behavior and privacy issues that still present significant challenges.

Q&A spotlights the development of one injection device that is helping change the treatment-adherence landscape.

With the patient voice growing louder in all aspects of the drug development and commercialization journey, Pharm Exec examines some of the current industry thinking on the evolving pharma-patient relationship.

The populist-driven shifts trumpeted from the US to the EU leaves plenty of question marks when trying to size up the trajectory of the global pharma industry. One certainty, however, will be change.